发明名称 COMPOSITION AND METHOD FOR TREATING COGNITIVE IMPAIRMENTS IN DOWN SYNDROM SUBJECTS
摘要 <p>This application relates to compounds having inverse agonist functional selectivity for GABA A receptors containing the a5 subunit for use as a medicament in the treatment of cognitive impairments in subjects suffering from Down syndrome. The present application also relates to the use of compounds having inverse agonist functional selectivity for GABA A receptors containing the a5 subunit for the preparation of a medicament in the treatment of cognitive impairments in subjects suffering from Down syndrome. The application further relates to pharmaceutical compositions for treating cognitive impairments in subjects suffering from Down syndrome comprising a compound having inverse agonist functional selectivity for GABA A receptors containing the a5 subunit, or suitable pharmaceutically acceptable salt thereof, a polyethoxylated castor oil and dimethyl sulfoxide (DMSO). The present application also describes methods for enhancing cognitive function, or treating or lessening the severity of cognitive impairments, in subjects suffering from Down syndrome by administering to a subject in need thereof a pharmaceutically effective amount of one or more compounds having inverse agonist functional selectivity for GABA A receptors containing the a5 subunit. More particularly, the present application is concerned with the treatment of cognitive impairments, such as impairment in memory, learning capacity or both, in subjects suffering from Down syndrome.</p>
申请公布号 WO2011024115(A1) 申请公布日期 2011.03.03
申请号 WO2010IB53796 申请日期 2010.08.24
申请人 CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS -;POTIER, MARIE-CLAUDE;DODD, ROBERT;DELATOUR, BENOIT;BRAUDEAU, JEROME;HERAULT, YANN 发明人 POTIER, MARIE-CLAUDE;DODD, ROBERT;DELATOUR, BENOIT;BRAUDEAU, JEROME;HERAULT, YANN
分类号 A61K31/381;A61K31/4162;A61K31/502;A61K31/5517;A61P25/28 主分类号 A61K31/381
代理机构 代理人
主权项
地址